Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
Abstract
The classical oral anticoagulants are increasingly being replaced in clinical practice by new antithrombotic drugs, which act by enabling direct inhibition of coagulation factor IIa (FIIa) or factor Xa (FXa). These drugs have multiple acronyms, including NOACs (new, non–vitamin K antagonist) or DOACs (direct oral anticoagulants), and currently include dabigatran (FIIa inhibitor), and rivaroxaban, apixaban, and edoxaban (FXa inhibitors). These drugs are approved for stroke prevention in patients with non-valvular atrial fibrillation and the prevention and treatment of venous thromboembolism. The "mantra" that DOACs do not require laboratory monitoring is not entirely correct because laboratory testing for drug effects is needed in many situations, because they influence hemostasis tests and in situations in which urgent measurement of DOACs is required. This should be very important to consider in the clinical situation for numbers of indications and increasing numbers of patients on DOACs therapy. The main aim of this article is to provide practical issues to general laboratory testing for DOACs, as well as to help avoid diagnostic errors associated with hemostasis testing. The assays for DOAC quantification must be available in medical centers on a whole day basis, to facilitate optimal drug management in conditions when things go wrong or in urgent cases of immediate reversal of anticoagulation or appropriate administration of a specific antidote.
References
Ageno W, Gallus AS, Wittkowsky A, et al. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 41(Suppl. 2):e44S-88S.
Antonijevic et al. Dabigatran – Metabolism, Pharmacologic Properties and Drug Interactions (Review article). Current Drug Metabolism 2017; 18(7):1-14.
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467-1507.
Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Center (FCSA). Thromb Haemost. 2011;106:868-76.
Baglin T. The role of the laboratory in treatment with new oral anticoagulants. Br J Haematol. 2013;163:160-7.
Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013;121:4032-5.
Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;6:511-20.
Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral anticoagulants. Br J Haematol. 2016,172:315-36.
Bauer KA. Targeted anti-anticoagulants. N Engl J Med. 2015;373:569–71.
Brieger D, Curnow J. Anticoagulation: A GP primer on the new oral anticoagulants. Aust Fam Physician. 2014;43(5):254-59.
Gouin-Thibault I, Delavenne X, Blanchard A, et al. Inter-individual variability in dabigatran and rivaroxaban exposure contribution of ABCB1 genetic polimorphisms and interaction with clarithromycin. J Thromb Haemost. 2017; 15:273-83.
Armando Tripodi, Simon Braham, Barbara Scimeca, Marco Moia, Flora Peyvandi. How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues. Arch Intern Med. 2018;128(6):379‑85.
Gosselin RC, Adcock DM. The laboratory 2015 perspective on direct oral anticoagulant testing. J Throm Haemost. 2016;14:886-93.
Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128-39.
Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013;59:353-62.
RC Gossselin, DM Adcock. The laboratory s 2015 perspective on dierect oral anticoagulant testing. J of Thrombosis and Haemostasis 2016;14(5):886-93.
Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost. 2013;11(Suppl 1):8–112.
Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assesment of the anticoagulant activity of direct oral anticoagulants: A systematic rewiew. Chest. 2017;151(1):127-35.
van Blerk M, Bailleul E, Chatelain B, et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost. 2015; 113: 154–64.
Weitz JI, Eikelboom JW. Urgent need to measure effects of direct oral anticoagulants. Circulation. 2016; 134: 186-8.
Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogn_eJM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012; 107: 985–97.
Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14: 623-7.
Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B,Dogn_e JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012;130:956–66.
Douxfils J, Chatelain C, Chatelain B, Dogn_e JM, Mullier F.Impact of apixaban on routine and specific coagulation assays: apractical laboratory guide. Thromb Haemost. 2013;110:283–94.
Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015;53:185-97.
Lippi G, Plebani M. Laboratory economics. Risk or opportunity? Clin Chem Lab Med 2016;54:1701-3.
Adam Cuker, Deborah M. Siegal, Mark A. Crowther, David A. Garcia. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. JACC. 2014; 64(11):1128-39.
Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5:1003-9.
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-9.
Favaloro EJ, et al. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis. Lab Medicine 2012; 43 (2): 1-10.
Favaloro EJ, et al. Laboratory investigation of thrombophilia: The good, the bad, and the ugly. Semin Thromb Hemost. 2009;35:695-710.
Tripodi A. Interference of new oral anticoagulants with frequently used coagulation tests. Clin Chem Lab Med. 2012; 50: 1501–3.
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014; 40: 163-71.
Tripodi A, et al. Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus 2018; 16: 462-70.
